SOUTH SAN FRANCISCO, Calif. — February 5, 2018 — FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of
oral small molecule drugs to activate the immune system against cancer, today announced the appointment of senior pharmaceutical research and development executive Michael F. Giordano, M.D., to its Board of Directors.
Dr. King points out that a number of
oral drug candidates inhibit PKC - delta and that it may be possible to suppress PKC - delta production with microRNAs (
small RNA
molecules that help to regulate protein generation).